Grandeur Peak Global Advisors LLC Acquires New Holdings in Haemonetics Corporation $HAE

Grandeur Peak Global Advisors LLC purchased a new position in shares of Haemonetics Corporation (NYSE:HAE) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,185 shares of the medical instruments supplier’s stock, valued at approximately $989,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nierenberg Investment Management Company LLC purchased a new position in Haemonetics in the second quarter worth approximately $1,971,000,000. Renaissance Technologies LLC acquired a new position in shares of Haemonetics during the first quarter worth $2,435,000. Rice Hall James & Associates LLC acquired a new stake in Haemonetics in the second quarter valued at $3,828,000. Aurora Investment Counsel purchased a new stake in Haemonetics during the 2nd quarter worth about $1,913,000. Finally, North Peak Capital Management LLC boosted its position in shares of Haemonetics by 204.4% during the 4th quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after acquiring an additional 740,626 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

Haemonetics stock opened at $105.04 on Friday. The company has a market cap of $4.78 billion, a P/E ratio of 51.49, a price-to-earnings-growth ratio of 2.13 and a beta of 0.52. Haemonetics Corporation has a one year low of $47.31 and a one year high of $109.57. The business has a fifty day moving average of $84.30 and a two-hundred day moving average of $69.72. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.91 and a current ratio of 3.08.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The company had revenue of $339.38 million for the quarter, compared to analyst estimates of $327.86 million. During the same period in the prior year, the business posted $1.10 earnings per share. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, analysts predict that Haemonetics Corporation will post 5.29 earnings per share for the current fiscal year.

More Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Zacks raised its FY2027 EPS forecast to $5.27 from $5.20, increased Q4 2027 expectations to $1.46 from $1.42, and lifted its Q1 2029 estimate to $1.41 from $1.33. The FY2029 forecast also edged up to $6.20 from $6.19, signaling somewhat stronger longer-term earnings potential. Haemonetics analyst estimates
• Neutral Sentiment: Zacks maintained forecasts of $5.67 EPS for FY2028 and $1.50 EPS for Q3 2028. Its current-year consensus estimate remains approximately $5.28–$5.29 per share, leaving the immediate earnings outlook broadly unchanged.
• Negative Sentiment: The research firm reduced estimates for several periods, including Q2 2027 EPS to $1.30 from $1.32, Q3 2027 to $1.36 from $1.37, Q1 2028 to $1.27 from $1.31, Q2 2028 to $1.44 from $1.45, Q3 2028 to $1.50 from $1.52, and FY2028 to $5.67 from $5.69. These cuts, particularly to nearer-term 2027–2028 results, likely contributed to the weaker trading despite the longer-term increases.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. BTIG Research upped their target price on shares of Haemonetics from $96.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Wall Street Zen raised shares of Haemonetics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Mizuho raised their price objective on Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Barrington Research lifted their target price on Haemonetics from $95.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 19th. Finally, Citigroup boosted their target price on Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $97.56.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.